Close Menu

NEW YORK -- OpGen announced after the close of the market on Tuesday an 8 percent revenue increase for the fourth quarter of 2019.

For the three months ended Dec. 31, 2019, OpGen's revenues grew to $821,674 from $758,959 million in Q4 2018. The company logged $570,674 in product revenue in Q4, and $250,000 in collaboration revenue.

Fourth quarter R&D expenses fell 42 percent to $1.1 million from $1.9 million, while SG&A costs dropped 19 percent to $1.7 million from $2.1 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.